Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 24, 2025 08:05 ET | Source: VivoSim Labs, Inc.

VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company”) announced that it has emerged from stealth mode to dramatically impact drug discovery and development....
April 23, 2025 08:05 ET | Source: Organovo, Inc.

VivoSim to Carry Forward Organovo 3D Bioprinting

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (the “Company”) announced that it will carry forward its 3D bioprinting and legacy technology as VivoSim Labs,...
April 02, 2025 08:05 ET | Source: Organovo, Inc.

Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements

SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment...
March 27, 2025 08:05 ET | Source: Organovo, Inc.

Organovo Provides Business Update

SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment...
March 25, 2025 11:25 ET | Source: Organovo, Inc.

Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company

SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment...
March 19, 2025 08:05 ET | Source: Organovo, Inc.

Organovo Announces Reverse Stock Split

SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel...
March 06, 2025 08:05 ET | Source: Organovo, Inc.

Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises

SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment...
February 25, 2025 08:05 ET | Source: Organovo, Inc.

Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment...
January 06, 2025 08:05 ET | Source: Organovo, Inc.

Organovo Announces Appointment of Norman Staskey as Chief Financial Officer

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel...
November 20, 2024 08:05 ET | Source: Organovo, Inc.

Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting

SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel...

Next Page keyboard_arrow_right